PepGen (PEPG) Research & Development (2021 - 2026)
PepGen (PEPG) reported Research & Development of $13.0 million for Q1 2026, down 48.76% on a YoY basis from $25.4 million in Q1 2025, and down 6.12% sequentially from $13.9 million in Q4 2025.
PepGen (PEPG) Research & Development (2021 - 2026) Analysis & Trends
PepGen (PEPG) has 6 years of Research & Development data on file, last reported at $13.0 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 48.76% year-over-year to $13.0 million; the trailing twelve-month figure through Mar 2026 stood at $58.7 million (down 32.66% YoY), and the FY2025 full-year result was $71.0 million, down 7.11% from the prior year.
- Research & Development retreated to $13.0 million in Q1 2026, from $13.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $25.4 million in Q1 2025 to a low of $10.7 million in Q1 2022.
- A 5-year average of $16.6 million and a median of $16.0 million in 2022 frame the typical range for Research & Development.
- Across the five-year window, Research & Development surged 342.79% in 2022 and tumbled 48.76% in 2026, its largest moves.
- Tracing PEPG's Research & Development over 5 years: stood at $13.2 million in 2022, then increased by 23.8% to $16.3 million in 2023, then rose by 16.33% to $19.0 million in 2024, then retreated by 26.95% to $13.9 million in 2025, then slipped by 6.12% to $13.0 million in 2026.
- Business Quant data shows PEPG's Research & Development at $13.0 million in Q1 2026, $13.9 million in Q4 2025, and $13.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | PepGen | 145.09 Mn | 145.09 Mn | - | 13.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.00 Mn |
| Dec 31, 2025 | 13.85 Mn |
| Sep 30, 2025 | 13.42 Mn |
| Jun 30, 2025 | 18.39 Mn |
| Mar 31, 2025 | 25.38 Mn |
| Dec 31, 2024 | 18.96 Mn |
| Sep 30, 2024 | 17.72 Mn |
| Jun 30, 2024 | 25.06 Mn |
| Mar 31, 2024 | 14.73 Mn |
| Dec 31, 2023 | 16.30 Mn |
| Sep 30, 2023 | 20.54 Mn |
| Jun 30, 2023 | 16.93 Mn |
| Mar 31, 2023 | 14.36 Mn |
| Dec 31, 2022 | 13.17 Mn |
| Sep 30, 2022 | 15.96 Mn |
| Jun 30, 2022 | 14.24 Mn |
| Mar 31, 2022 | 10.71 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | 5.71 Mn |
| Jun 30, 2021 | 3.22 Mn |